<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396381</url>
  </required_header>
  <id_info>
    <org_study_id>ZRHR-ERS-09-US</org_study_id>
    <secondary_id>ZRHR-ERS-09-US</secondary_id>
    <nct_id>NCT02396381</nct_id>
  </id_info>
  <brief_title>Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks</brief_title>
  <official_title>A Randomized, Controlled, 2-arm Parallel Group, Multi-center Study, to Evaluate Biological and Functional Changes in Healthy Smokers Switching to Tobacco Heating System 2.2 (THS 2.2) Compared to Continuing Smoking Conventional Cigarettes for 26 Weeks in an Ambulatory Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to demonstrate clinical, biological and functional health changes in
      smokers switching to the candidate modified risk tobacco product: Tobacco Heating System 2.2
      (THS 2.2) as compared to smokers continuing smoking their conventional cigarettes (CC) over a
      26-week period.

      To characterize the study as successful, at least 5 clinical risk endpoints should move in
      the direction of smoking cessation and these results would be statistically significant. The
      main analysis will be defined a priori (using the Hailperin-Ruger approach) and will be made
      between THS 2.2 use and CC use as &quot;per actual product used&quot; and product use categories.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical, biological and functional endpoints to be measured in this study (&quot;smoker's
      health profile&quot;) may characterize the modification of risk of smoking-related diseases.

      Clinical risk endpoint to be assessed are selected based on a) their association to
      smoking-related diseases b) their association to smoking status, c) their reversibility upon
      smoking cessation, and d) their suitability to be measured with valid and robust methods in
      clinical studies.

      The biological markers, functional markers and biomarkers of exposure (BoExp) with the
      strongest scientific evidence will constitute the 'smoker's health profile' and will be
      measured as the primary objective of the study.

      Additional endpoints involved in the mechanistic of smoking-related diseases will be studied
      to provide additional scientific evidence to strengthen the primary objective.

      The study will provide a perspective of product usage in a &quot;real world setting&quot; where smoking
      CC in addition to THS 2.2 may be expected.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2015</start_date>
  <completion_date type="Actual">August 1, 2017</completion_date>
  <primary_completion_date type="Actual">September 13, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Levels of High Density Lipoprotein C (HDL-C).</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Concentrations measured in serum.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of White Blood Cells (WBC).</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Concentrations measured in blood.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1).</measure>
    <time_frame>26 Weeks</time_frame>
    <description>FEV1 post-bronchodilator and expressed as percentage predicted (FEV1 %pred).
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of Soluble Intercellular Adhesion Molecule 1 (sICAM-1).</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Concentrations measured in serum.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of 11-dehydrothromboxane B2 (11-DTXB2).</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of 8-epi-prostaglandin F2α (8-epi-PGF2α).</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL).</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent Change From Baseline of Carboxyhemoglobin (COHb)</measure>
    <time_frame>26 Weeks</time_frame>
    <description>Carboxyhemoglobin (COHb) is assayed from whole blood.
Geometric Least Squares means are provided as descriptive statistics. Expressed as % of saturation of hemoglobin.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1039</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>THS 2.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad libitum use of THS 2.2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ad libitum use of CC</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>THS 2.2</intervention_name>
    <description>Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks</description>
    <arm_group_label>THS 2.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CC</intervention_name>
    <description>Ad libitum use of CC in an ambulatory setting for 26 weeks</description>
    <arm_group_label>CC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current healthy smoker as judged by the Principal Investigator(s) or designee(s)

          -  Minimum age: 30 years old

          -  Have smoked for the last 10 years

          -  Have smoked more than 10 non menthol CC/day on average (no brand restriction) over the
             past year

        Exclusion Criteria:

          -  Clinically relevant medical conditions that in the opinion of the investigators would
             jeopardize the safety of the participant.

          -  Subject who has (FEV1/FVC) &lt; 0.7 and FEV1 &lt; 80% predicted value at post-bronchodilator
             spirometry

          -  Subject with asthma condition (post-bronchodilator FEV1/FVC &lt; 0.75 and reversibility
             in FEV1 ≥ 12% and &gt; 200 mL from pre- to post-bronchodilator values)

          -  Subject who took or is taking concomitant medication which may have an impact on the
             &quot;smoker's heath profile&quot;

          -  Female subject is pregnant or breast feeding.

          -  Female subject who does not agree to use an acceptable method of effective
             contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Danielle Armas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion Arizona</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leonard Dunn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research West Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hugh Coleman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Stoica, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Compass Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Kentucky Research Associate</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Davidson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion Lincoln</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Rubino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Raleigh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Raad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Charlotte</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kevin Cannon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Wilmington</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Derek Schroder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Cary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephanie Powell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PMG Research of Bristol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NOCCR</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darrell Herrington, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benchmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence Chu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benchmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Seger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Benchmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lon Lynn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research West Florida</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Subich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Compass Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabel Kuhare-Arcure, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Midwest Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keith Scott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion Arizona</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance, Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research West Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compass Research</name>
      <address>
        <city>The Villages</city>
        <state>Florida</state>
        <zip>32162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associate</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Celerion Lincoln</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Cary</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Raleigh</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research of Bristol</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NOCCR</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benchmark</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Clinical Research</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <results_first_submitted>July 27, 2018</results_first_submitted>
  <results_first_submitted_qc>August 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2019</results_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Candidate modified risk tobacco product</keyword>
  <keyword>Conventional cigarette</keyword>
  <keyword>Exposure response</keyword>
  <keyword>Smoking</keyword>
  <keyword>Tobacco Heating System</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Following randomization of 984 subjects, from 1039 enrolled subjects, one clinical site was terminated from this study due to non-GCP compliance.
The safety population of 1012 subjects included all enrolled subjects except 27 subjects from the terminated site.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>THS 2.2 Group</title>
          <description>Randomized to Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks</description>
        </group>
        <group group_id="P2">
          <title>CC Group</title>
          <description>Randomized to Ad libitum use of CC in an ambulatory setting for 26 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="488"/>
                <participants group_id="P2" count="496"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set - As Exposed (FAS-EX)</title>
              <participants_list>
                <participants group_id="P1" count="414"/>
                <participants group_id="P2" count="443"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="381"/>
                <participants group_id="P2" count="422"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study procedures</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of town/state</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Could not complete visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Possible conflict of interest</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomization/Screening Error</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set - As Exposed (FAS-EX)</population>
      <group_list>
        <group group_id="B1">
          <title>THS 2.2 Use</title>
          <description>≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.</description>
        </group>
        <group group_id="B2">
          <title>CC Use</title>
          <description>≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.</description>
        </group>
        <group group_id="B3">
          <title>Dual Use</title>
          <description>≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC-use categories do not apply to 50% of these days.</description>
        </group>
        <group group_id="B4">
          <title>Other Use</title>
          <description>Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns between consecutive analysis periods.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="245"/>
            <count group_id="B2" value="428"/>
            <count group_id="B3" value="142"/>
            <count group_id="B4" value="42"/>
            <count group_id="B5" value="857"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.2" spread="9.64"/>
                    <measurement group_id="B2" value="45.2" spread="9.55"/>
                    <measurement group_id="B3" value="43.8" spread="9.77"/>
                    <measurement group_id="B4" value="44.2" spread="8.14"/>
                    <measurement group_id="B5" value="44.6" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                    <measurement group_id="B2" value="182"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="353"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="246"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="504"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="228"/>
                    <measurement group_id="B2" value="400"/>
                    <measurement group_id="B3" value="135"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="804"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="195"/>
                    <measurement group_id="B2" value="341"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="30"/>
                    <measurement group_id="B5" value="679"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="3.99"/>
                    <measurement group_id="B2" value="27.1" spread="4.13"/>
                    <measurement group_id="B3" value="26.9" spread="4.35"/>
                    <measurement group_id="B4" value="26.9" spread="5.12"/>
                    <measurement group_id="B5" value="27.0" spread="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Levels of High Density Lipoprotein C (HDL-C).</title>
        <description>Concentrations measured in serum.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>26 Weeks</time_frame>
        <population>Full Analysis Set – As Exposed (FAS-EX)</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC-use categories do not apply to 50% of these days.</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns between consecutive analysis periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of High Density Lipoprotein C (HDL-C).</title>
          <description>Concentrations measured in serum.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>Full Analysis Set – As Exposed (FAS-EX)</population>
          <units>mg/dL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.1" lower_limit="51.4" upper_limit="56.7"/>
                    <measurement group_id="O2" value="50.9" lower_limit="49.4" upper_limit="52.4"/>
                    <measurement group_id="O3" value="56.3" lower_limit="52.7" upper_limit="59.9"/>
                    <measurement group_id="O4" value="52.8" lower_limit="47.4" upper_limit="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will test if the mean level of HDL-C for THS-use is greater than for CC-use. The following hypothesis will be evaluated:
H0: XTHS - XCC ≤ 0.0
HA: XTHS - XCC &gt; 0.0
where XTHS and XCC are the adjusted means of THS-use and CC-use, respectively. H0 is rejected with a type I error α = 1.5625% (one-sided test).</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Hailperin-Rüger</method>
            <method_desc>p-value less than 1.5625% would be considered statistically significant, following test multiplicity adjustment using the Hailperin-Rüger approach</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.09</param_value>
            <ci_percent>96.875</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>5.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Levels of White Blood Cells (WBC).</title>
        <description>Concentrations measured in blood.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>26 Weeks</time_frame>
        <population>Full Analysis Set – As Exposed (FAS-EX)</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC-use categories do not apply to 50% of these days.</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns between consecutive analysis periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of White Blood Cells (WBC).</title>
          <description>Concentrations measured in blood.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>Full Analysis Set – As Exposed (FAS-EX)</population>
          <units>GI/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.98" lower_limit="6.70" upper_limit="7.25"/>
                    <measurement group_id="O2" value="7.48" lower_limit="7.28" upper_limit="7.69"/>
                    <measurement group_id="O3" value="7.41" lower_limit="7.00" upper_limit="7.82"/>
                    <measurement group_id="O4" value="8.71" lower_limit="7.80" upper_limit="9.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will test if the mean level of WBC for THS-use is lower than for CC-use. The following hypothesis will be evaluated:
H0: XTHS - XCC ≥ 0.0
HA: XTHS - XCC &lt; 0.0
where XTHS and XCC are the adjusted means of THS-use and CC-use, respectively. H0 is rejected with a type I error α = 1.5625% (one-sided test).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Hailperin-Rüger</method>
            <method_desc>p-value less than 1.5625% would be considered statistically significant, following test multiplicity adjustment using the Hailperin-Rüger approach</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.420</param_value>
            <ci_percent>96.875</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.717</ci_lower_limit>
            <ci_upper_limit>-0.123</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1).</title>
        <description>FEV1 post-bronchodilator and expressed as percentage predicted (FEV1 %pred).
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>26 Weeks</time_frame>
        <population>Full Analysis Set – As Exposed (FAS-EX)</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC-use categories do not apply to 50% of these days.</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns between consecutive analysis periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1).</title>
          <description>FEV1 post-bronchodilator and expressed as percentage predicted (FEV1 %pred).
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>Full Analysis Set – As Exposed (FAS-EX)</population>
          <units>Percent of predicted FEV1</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" lower_limit="93.7" upper_limit="97.1"/>
                    <measurement group_id="O2" value="93.4" lower_limit="92.0" upper_limit="94.8"/>
                    <measurement group_id="O3" value="93.7" lower_limit="91.3" upper_limit="96.0"/>
                    <measurement group_id="O4" value="94.3" lower_limit="89.3" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will test if the mean level of FEV1 for THS-use is greater than for CC-use. The following hypothesis will be evaluated:
H0: XTHS - XCC ≤ 0.0
HA: XTHS - XCC &gt; 0.0
where XTHS and XCC are the adjusted means of THS-use and CC-use, respectively. H0 is rejected with a type I error α = 1.5625% (one-sided test).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.008</p_value>
            <method>Hailperin-Rüger</method>
            <method_desc>p-value less than 1.5625% would be considered statistically significant, following test multiplicity adjustment using the Hailperin-Rüger approach</method_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.28</param_value>
            <ci_percent>96.875</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.145</ci_lower_limit>
            <ci_upper_limit>2.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of Soluble Intercellular Adhesion Molecule 1 (sICAM-1).</title>
        <description>Concentrations measured in serum.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>26 Weeks</time_frame>
        <population>Full Analysis Set – As Exposed (FAS-EX)</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC-use categories do not apply to 50% of these days.</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns between consecutive analysis periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Soluble Intercellular Adhesion Molecule 1 (sICAM-1).</title>
          <description>Concentrations measured in serum.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>Full Analysis Set – As Exposed (FAS-EX)</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="252" lower_limit="239" upper_limit="266"/>
                    <measurement group_id="O2" value="266" lower_limit="253" upper_limit="279"/>
                    <measurement group_id="O3" value="270" lower_limit="253" upper_limit="288"/>
                    <measurement group_id="O4" value="273" lower_limit="234" upper_limit="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis of sICAM-1 will test if the mean level of this clinical risk endpoint for THS-use is lower relative to CC-use. The following hypothesis will be evaluated:
H0: XTHS / XCC ≥ 1.0
HA: XTHS / XCC &lt; 1.0
where XTHS and XCC are the adjusted geometrical means of THS-use and CC-use, respectively. H0 is rejected with a type I error α = 1.5625% (one-sided test).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>Hailperin-Rüger</method>
            <method_desc>p-value less than 1.5625% would be considered statistically significant, following test multiplicity adjustment using the Hailperin-Rüger approach</method_desc>
            <param_type>% Reduction</param_type>
            <param_value>2.86</param_value>
            <ci_percent>96.875</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.426</ci_lower_limit>
            <ci_upper_limit>6.04</ci_upper_limit>
            <estimate_desc>Derived as 1 – LS Mean Ratio (THS / CC)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of 11-dehydrothromboxane B2 (11-DTXB2).</title>
        <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>26 Weeks</time_frame>
        <population>Full Analysis Set – As Exposed (FAS-EX)</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC-use categories do not apply to 50% of these days.</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns between consecutive analysis periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of 11-dehydrothromboxane B2 (11-DTXB2).</title>
          <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>Full Analysis Set – As Exposed (FAS-EX)</population>
          <units>pg/mg creat</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="496" lower_limit="446" upper_limit="551"/>
                    <measurement group_id="O2" value="523" lower_limit="482" upper_limit="568"/>
                    <measurement group_id="O3" value="532" lower_limit="464" upper_limit="610"/>
                    <measurement group_id="O4" value="626" lower_limit="504" upper_limit="777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis of 11-DTX-B2 will test if the mean level of this clinical risk endpoint for THS-use is lower relative to CC-use. The following hypothesis will be evaluated:
H0: XTHS / XCC ≥ 1.0
HA: XTHS / XCC &lt; 1.0
where XTHS and XCC are the adjusted geometrical means of THS-use and CC-use, respectively. H0 is rejected with a type I error α = 1.5625% (one-sided test).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.193</p_value>
            <method>Hailperin-Rüger</method>
            <method_desc>p-value less than 1.5625% would be considered statistically significant, following test multiplicity adjustment using the Hailperin-Rüger approach</method_desc>
            <param_type>% Reduction</param_type>
            <param_value>4.74</param_value>
            <ci_percent>96.875</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.5</ci_lower_limit>
            <ci_upper_limit>15.6</ci_upper_limit>
            <estimate_desc>Derived as 1 – LS Mean Ratio (THS / CC)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of 8-epi-prostaglandin F2α (8-epi-PGF2α).</title>
        <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>26 Weeks</time_frame>
        <population>Full Analysis Set – As Exposed (FAS-EX)</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC-use categories do not apply to 50% of these days.</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns between consecutive analysis periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of 8-epi-prostaglandin F2α (8-epi-PGF2α).</title>
          <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>Full Analysis Set – As Exposed (FAS-EX)</population>
          <units>pg/mg creat</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321" lower_limit="299" upper_limit="344"/>
                    <measurement group_id="O2" value="351" lower_limit="334" upper_limit="369"/>
                    <measurement group_id="O3" value="347" lower_limit="318" upper_limit="377"/>
                    <measurement group_id="O4" value="335" lower_limit="281" upper_limit="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis of 8-epi-PGF2α will test if the mean level of this clinical risk endpoint for THS-use is lower relative to CC-use. The following hypothesis will be evaluated:
H0: XTHS / XCC ≥ 1.0
HA: XTHS / XCC &lt; 1.0
where XTHS and XCC are the adjusted geometrical means of THS-use and CC-use, respectively. H0 is rejected with a type I error α = 1.5625% (one-sided test).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Hailperin-Rüger</method>
            <method_desc>p-value less than 1.5625% would be considered statistically significant, following test multiplicity adjustment using the Hailperin-Rüger approach</method_desc>
            <param_type>% Reduction</param_type>
            <param_value>6.80</param_value>
            <ci_percent>96.875</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.216</ci_lower_limit>
            <ci_upper_limit>13.3</ci_upper_limit>
            <estimate_desc>Derived as 1 – LS Mean Ratio (THS / CC)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL).</title>
        <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
        <time_frame>26 Weeks</time_frame>
        <population>Full Analysis Set – As Exposed (FAS-EX)</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC-use categories do not apply to 50% of these days.</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns between consecutive analysis periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL).</title>
          <description>Concentrations measured in urine and expressed as concentration adjusted for creatinine.
Geometric Least Squares means are provided as descriptive statistics.</description>
          <population>Full Analysis Set – As Exposed (FAS-EX)</population>
          <units>pg/mg creat</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="144" lower_limit="118" upper_limit="175"/>
                    <measurement group_id="O2" value="282" lower_limit="254" upper_limit="314"/>
                    <measurement group_id="O3" value="286" lower_limit="244" upper_limit="334"/>
                    <measurement group_id="O4" value="342" lower_limit="254" upper_limit="460"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis of Total NNAL will test if the mean level of this clinical risk endpoint for THS-use is lower relative to CC-use. The following hypothesis will be evaluated:
H0: XTHS / XCC ≥ 1.0
HA: XTHS / XCC &lt; 1.0
where XTHS and XCC are the adjusted geometrical means of THS-use and CC-use, respectively. H0 is rejected with a type I error α = 1.5625% (one-sided test).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Hailperin-Rüger</method>
            <method_desc>p-value less than 1.5625% would be considered statistically significant, following test multiplicity adjustment using the Hailperin-Rüger approach</method_desc>
            <param_type>% Reduction</param_type>
            <param_value>43.5</param_value>
            <ci_percent>96.875</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>33.7</ci_lower_limit>
            <ci_upper_limit>51.9</ci_upper_limit>
            <estimate_desc>Derived as 1 – LS Mean Ratio (THS / CC)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent Change From Baseline of Carboxyhemoglobin (COHb)</title>
        <description>Carboxyhemoglobin (COHb) is assayed from whole blood.
Geometric Least Squares means are provided as descriptive statistics. Expressed as % of saturation of hemoglobin.</description>
        <time_frame>26 Weeks</time_frame>
        <population>Full Analysis Set – As Exposed (FAS-EX)</population>
        <group_list>
          <group group_id="O1">
            <title>THS 2.2 Use</title>
            <description>≥1 THS 2.2 or CC, and ≥70% THS 2.2 use over the analysis period, and ≥70% THS 2.2 use on &gt;50% of days in the analysis period.</description>
          </group>
          <group group_id="O2">
            <title>CC Use</title>
            <description>≥1 THS 2.2 or CC use, and &lt;1% THS 2.2 use over the entire analysis period and &lt;1% THS 2.2 use on ≥ 50% of days in the analysis period.</description>
          </group>
          <group group_id="O3">
            <title>Dual Use</title>
            <description>≥ 1 THS 2.2 or CC and, 1% ≤THS 2.2 &lt;70% over the analysis period, or THS 2.2-use and CC-use categories do not apply to 50% of these days.</description>
          </group>
          <group group_id="O4">
            <title>Other Use</title>
            <description>Subjects with missing product use data, subjects using e-cigarettes or other tobacco products, quitters, or subjects who switched across different use patterns between consecutive analysis periods.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline of Carboxyhemoglobin (COHb)</title>
          <description>Carboxyhemoglobin (COHb) is assayed from whole blood.
Geometric Least Squares means are provided as descriptive statistics. Expressed as % of saturation of hemoglobin.</description>
          <population>Full Analysis Set – As Exposed (FAS-EX)</population>
          <units>percentage change from baseline</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="428"/>
                <count group_id="O3" value="142"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" lower_limit="2.51" upper_limit="3.20"/>
                    <measurement group_id="O2" value="4.38" lower_limit="4.16" upper_limit="4.61"/>
                    <measurement group_id="O3" value="4.23" lower_limit="3.80" upper_limit="4.70"/>
                    <measurement group_id="O4" value="5.59" lower_limit="4.87" upper_limit="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analysis will test if the mean level of COHb for THS-use is lower relative to CC-use. The following hypothesis will be evaluated:
H0: XTHS / XCC ≥ 1.0
HA: XTHS / XCC &lt; 1.0
where XTHS and XCC are the adjusted geometrical means of THS-use and CC-use. H0 is rejected with a type I error α = 1.5625% (one-sided test).</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Hailperin-Rüger</method>
            <method_desc>p-value less than 1.5625% would be considered statistically significant, following test multiplicity adjustment using the Hailperin-Rüger approach</method_desc>
            <param_type>% Reduction</param_type>
            <param_value>32.2</param_value>
            <ci_percent>96.875</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>24.5</ci_lower_limit>
            <ci_upper_limit>39</ci_upper_limit>
            <estimate_desc>Derived as 1 – LS Mean Ratio (THS / CC)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The entire study duration per subject was between 32 to 38 weeks, including a Screening period of up to 42 days prior to enrollment, a 6 to 10-day run-in period prior to randomization, followed by a 26 week randomized exposure period. The end of study for a subject was defined as the check-out or the date of early termination of the subject plus the 28 day Safety Follow-up period, unless the subject was lost to follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>THS 2.2 Group</title>
          <description>Randomized to Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks</description>
        </group>
        <group group_id="E2">
          <title>CC Group</title>
          <description>Randomized to Ad libitum use of CC in an ambulatory setting for 26 weeks</description>
        </group>
        <group group_id="E3">
          <title>Product Test</title>
          <description>Enrolled subjects who participated in a product test, but were not randomized.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute, with Urosepsis and Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tooth Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Head injury with seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Vertebral osteophyte with Cervical myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Metastases to small intestine with anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="477"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood and bereavement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="477"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="477"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="483"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="477"/>
                <counts group_id="E2" events="33" subjects_affected="29" subjects_at_risk="483"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.
The Intellectual Property rights and research results from the present study belong to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christelle Haziza</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 58 242 11 11</phone>
      <email>ClinicalTrials.PMI@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

